Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 844-232-8 | CAS number: 102731-54-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 2017-04-24 to 2017-05-12
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guidelines for the Testing of Chemicals: OECD 442E; In vitro Skin Sensitisation: human Cell Line Activation Test (h-CLAT)
- Version / remarks:
- July 2016
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- activation of dendritic cells
Test material
- Reference substance name:
- 3-hydroxypropyl octanoate
- EC Number:
- 844-232-8
- Cas Number:
- 102731-54-4
- Molecular formula:
- C11H22O3
- IUPAC Name:
- 3-hydroxypropyl octanoate
Constituent 1
In vitro test system
- Details on the study design:
- The test item concentrations investigated in the main experiment (h-CLAT) were determined with two XTT tests.
Main test:
The test item was tested in two independent runs.
For the test item exposure the highest dose solution calculated from the XTT assay was prepared corresponding to 1.2 × CV75 (first XTT CV75: 384.6μg/mL; second XTT CV75: 256.7μg/mL; mean CV75: 320.65 μg/mL). Further 7 dilutions were prepared by serial 1:1.2 dilution. The dilutions were prepared freshly before each experiment.
Each volume (500 μL) of the dilutions of the test item, medium control, positive and DMSO control was added to the cells. The treated THP-1 cells were incubated for 24 ± 0.5 hours.
Each concentration of the test item, medium control, positive and DMSO control was prepared in triplicates for the different staining (with FITC-labelled anti-CD86, CD54 antibody or mouse IgG1).
During flow cytometry acquisition dead cells were gated-out by staining with 7-AAD. Gating by FSC (forward scatter) and SSC (side scatter) was not done. A total of 10,000 living cells were analysed. Mean fluorescence intensity (MFI) of viable cells and viability for each sample were used for analysis. The other tubes were acquired without changing the settings of the cytometer. The MFI was recorded for each condition. The relative fluorescence intensity (RFI) was not calculated, if the cell viability was less than 50 % (due to diffuse labelling of cytoplasmic structures that are generated due to cell membrane destruction).
Acceptance Criteria
The following acceptance criteria should be met when using the h-CLAT method:
• Cell viability of medium control is adjusted to 100 % and the cell viability of the DMSO control should be more than 90 % in comparison to the medium control.
• In the solvent/vehicle control (i.e. DMSO), RFI values compared to the medium control of both CD86 and CD54 should not exceed the positive criteria (CD86 ≥ 150 % and CD54 ≥ 200 %).
• For both medium and solvent/vehicle controls (i.e. DMSO), the MFI ratio of CD86 and CD54 to isotype control should be > 105 %.
• In the positive control (DNCB), RFI values of both CD86 and CD54 should meet the positive criteria (CD86 ≥ 150 % and CD54 ≥ 200 %) and the cell viability should be > 50%.
• For the test chemical, the cell viability should be more than 50 % in at least four tested
concentrations in each run.
Negative results are acceptable only for test items exhibiting a cell viability of < 90 % at the highest concentration tested (i.e. 1.2 × CV75). If the cell viability at 1.2 × CV75 is ≥ 90 % the negative result should be discarded. In such a case it is recommended to try to refine the dose selection by repeating the CV75 determination. It should be noted that when 5000 μg/mL in saline (or medium or other solvents/vehicles), 1000 μg/mL in DMSO or the highest soluble concentration is used as the maximal test concentration of a test chemical, a negative result is acceptable even if the cell viability > 90 %.
Prediction model
For CD86/CD54 expression measurement, each test item is tested in at least two independent runs to derive a single prediction (POSITIVE or NEGATIVE). An h-CLAT prediction is considered POSITIVE if at least one of the following conditions is met in 2 of 2 or in at least 2 of 3 independent runs:
− The RFI of CD86 is ≥ 150 % at any tested concentration (with cell viability ≥ 50 %);
− The RFI of CD54 is ≥ 200 % at any tested concentration (with cell viability ≥ 50 %).
Otherwise, the h-CLAT prediction is considered NEGATIVE.
Based on the above, if the first two runs are both positive for CD86 and/or are both positive for CD54, the h-CLAT prediction is considered POSITIVE and a third run does not need to be conducted. Similarly, if the first two runs are negative for both markers, the h-CLAT prediction is considered NEGATIVE without the need for a third run. If however, the first two runs are not concordant for at least one of the markers (CD54 or CD86), a third run is needed and the final prediction will be based on the majority result of the three individual runs (i.e. 2 out of 3). In this respect, it should be noted that if two independent runs are conducted and one is only positive for CD86 (hereinafter referred to as P1) and the other is only positive for CD54 (hereinafter referred to as P2), a third run is required. If this third run is negative for both markers (hereinafter referred to as N), the h-CLAT prediction is considered NEGATIVE. On the other hand, if the third run is positive for either marker (P1 or P2) or for both markers (hereinafter referred to as P12), the h-CLAT prediction is considered POSITIVE.
Results and discussion
In vitro / in chemico
Resultsopen allclose all
- Key result
- Run / experiment:
- other: other: 2; 321 μg/mL
- Parameter:
- other: RFI of CD54
- Value:
- 206.7
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- positive indication of skin sensitisation
- Key result
- Run / experiment:
- other: other: 2; 223 μg/mL
- Parameter:
- other: RFI of CD86
- Value:
- 158
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- positive indication of skin sensitisation
- Other effects / acceptance of results:
- ACCEPTANCE OF RESULTS:
- Acceptance criteria met for solvent control: yes
- Acceptance criteria met for positive control: yes
Any other information on results incl. tables
The CV75 value of the first XTT test: 384.6 μg/mL
The CV75 value of the second XTT test: 256.7 μg/mL
The mean CV75 value of both XTT tests: 320.65 μg/mL
Table 1: Results of h-CLAT runs
Concentration (μg/mL) | RFI (%) CD 54 Antibody | RFI (%) CD 86 Antibody | Cell Viability (%) | |
1st h-CLAT run | ||||
Medium Control | - | 100 | 100 | 100 |
DMSO Control | - | 100 | 100 | 100 |
Positive Control (DNCB) | 2 | 219# | 711.7# | 80.6 |
3 | 358.3# | 734.4# | 73 | |
Test Item | 107 | 113.8 | 124.4 | 104 |
129 | 114.4 | 101.9 | 105.8 | |
155 | 109 | 109.6 | 102.4 | |
186 | 129.3 | 131.4 | 99.3 | |
223 | 150.9 | 151.3# | 97.6 | |
267 | 160.5 | 169.9# | 97.2 | |
321 E | 224# | 549.4# | 37.5 | |
385 E | 345.5# | 3460.3# | 3.8 | |
2nd h-CLAT run | ||||
Medium Control | - | 100 | 100 | 100 |
DMSO Control | - | 100 | 100 | 100 |
Positive Control (DNCB) | 2 | 229.6# | 396.4# | 81.7 |
3 | 219.9# | 385.1# | 77.9 | |
Test Item | 107 | 115.6 | 101.3 | 105.4 |
129 | 112.8 | 112.1 | 105.8 | |
155 | 125.6 | 114.6 | 106.4 | |
186 | 146.1 | 136.9 | 105.9 | |
223 | 173.3 | 158# | 108.3 | |
267 | 188.9 | 179# | 104 | |
321 | 206.7# | 343.9# | 70.9 | |
385 E | 272.2# | 1317.2# | 13.9 |
E=cell viability below 50 %, are excluded from the evaluation
#=RFI value of CD86 or CD54 fulfilled the positive criteria (CD86 ≥ 150 % and CD54 ≥ 200 %)
Applicant's summary and conclusion
- Interpretation of results:
- Category 1 (skin sensitising) based on GHS criteria
- Conclusions:
- In the h-CLAT study the test item is considered to have a skin sensitization potential.
- Executive summary:
An in vitro Human Cell Line Activation Test (h-CLAT) according to OECD 442E was performed to assess the skin sensitizating potential of the test item dissolved in culture medium when administered to THP-1 cells for 24 ± 0.5 hours. The highest test item concentration for the main experiment (h-CLAT) of the test item was previously determined by two XTT tests. Cytotoxic effects were observed following incubation with the test item starting with the concentration of 625 μg/mL in the first XTT test and of 312.5 μg/mL in the second XTT test up to the highest tested concentration (5000 μg/mL). The mean CV75 value of both XTT tests was calculated as 320.65 μg/mL. The following concentrations of the test item (dissolved in culture medium) were tested in the main experiment (h-CLAT): 107, 129, 155, 186, 223, 267, 321 and 385 μg/mL
The test item with a calculated log Pow of 2.84 was tested in 2 independent runs. The cell viability of the two highest tested test item concentrations of the first run and the highest concentration of the second run were below 50 % and therefore excluded from the evaluation. The RFI of CD86 was equal or greater than 150 % in at least one concentration of both independent run data. In addition, the RFI of CD54 was greater than 200 % in one tested concentration of the second run. Both runs were POSITIVE relating to the prediction model used in the h-CLAT test method, therefore the test item is considered to have a skin sensitization potential. In the DMSO solvent control, RFI values compared to the medium control of both CD54 and CD86 did not exceed the positive criteria (CD54 ≥ 200 % and CD86 ≥ 150 %). The RFI values of the positive controls (DNCB) for CD54 and CD86 exceeded the positive criteria (CD54 ≥ 200 % and CD86 ≥ 150 %) and the cell viability was >50 %. In conclusion, the test item activated THP-1 cells under the test conditions of this study. Therefore the test item is considered to be positive for the third key event of the skin sensitisation Adverse Outcome Pathway (AOP).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
